Schizophrenia has a heritability of 60–80% 1 , much of which is attributable to common risk
alleles. Here, in a two-stage genome-wide association study of up to 76,755 individuals with …

Polygenic risk scores have shown great promise in predicting complex disease risk and will
become more accurate as training sample sizes increase. The standard approach for …

Regulatory and coding variants are known to be enriched with associations identified by
genome-wide association studies (GWASs) of complex disease, but their contributions to trait …

OBJECTIVE: We assessed efficacy and tolerability of the injectable atypical antipsychotic
paliperidone palmitate in delaying time-to-relapse in adults with schizophrenia. METHODS: …

This study assessed the efficacy and the safety of a dosing regimen that was revised from
earlier studies for the investigational injectable atypical antipsychotic paliperidone palmitate (…

Importance Treatment nonadherence and relapse are common problems in patients with
schizophrenia. The long-acting 3-month formulation of paliperidone palmitate, owing to its …

Background: This double-blind, parallel-group, multicenter, phase-3 study was designed to
test the noninferiority of paliperidone palmitate 3-month formulation (PP3M) to the currently …

This 13-week, double-blind study evaluated the efficacy and safety of the atypical
antipsychotic paliperidone palmitate (recently approved in the United States) versus placebo …

Background Polygenic scores (PGSs), which assess the genetic risk of individuals for a disease,
are calculated as a weighted count of risk alleles identified in genome-wide association …

This 13-week double-blind study was designed to assess noninferiority of the recently
approved (in the US) injectable atypical antipsychotic paliperidone palmitate (PP) versus …